Review article · 2023 · Open access
Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities
International Journal of Molecular Sciences, 24(6), 5205 · Published 8 March 2023 · DOI 10.3390/ijms24065205
In brief
“Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities” is a 2023 review article by Pingping Yang and 2 co-authors, published in International Journal of Molecular Sciences. OpenAlex counts 39 citations as of 19 November 2026, which puts it in the top 7% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at International Journal of Molecular Sciences.
- Citations
- 39
- Most cited in
- 2025 (14)
- Field-weighted impact
- 0.55
- References
- 93
- Authors
- 3
Abstract
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Although a cadre of therapeutic strategies have been made available for CVDs in the clinical setting, predominantly through medication and surgery, these do not fully address the clinical needs of patients with CVD. As a new technique for CVD treatment, nanocarriers are employed to modify and package medications to ease the targeting of tissues, cells and molecules within the cardiovascular system. Nanocarriers are made of biomaterials, metals, or a combination of these materials, with sizes similar to bioactive molecules such as proteins and DNA. Cardiovascular nanomedicine (CVN) has only surfaced in recent years and is still in its infancy. Ample studies have displayed promise for the clinical utility of nanomedicine techniques, courtesy of continued perfection in nanocarrier design to optimize drug delivery and treatment outcomes. Here in this review, we will summarize the research advances in the literature on nanoparticles in the management of CVDs, including ischemic and coronary heart disease (e.g., atherosclerosis, angina pectoris and myocardial infarction), myocardial ischemia-reperfusion injury, aortic aneurysm, myocarditis, hypertension, and pulmonary artery hypertension and thrombosis.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Yang, P., Ren, J. T., & Yang, L. (2023). Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities. International Journal of Molecular Sciences, 24(6), 5205. https://doi.org/10.3390/ijms24065205
MLA 9
Yang, Pingping, et al. “Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities.” International Journal of Molecular Sciences, vol. 24, no. 6, 2023, p. 5205. https://doi.org/10.3390/ijms24065205.
Chicago
Yang, Pingping, Jun Tao Ren, and Lifang Yang. 2023. “Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities.” International Journal of Molecular Sciences 24 (6): 5205. https://doi.org/10.3390/ijms24065205.
Harvard
Yang, P., Ren, J. T. and Yang, L. (2023) ‘Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities’, International Journal of Molecular Sciences, 24(6), p. 5205. doi:10.3390/ijms24065205.
IEEE
P. Yang, J. T. Ren, and L. Yang, “Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities,” International Journal of Molecular Sciences, vol. 24, no. 6, p. 5205, 2023, doi: 10.3390/ijms24065205.
BibTeX
@article{yang2023nanoparticles,
title = {{Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities}},
author = {Yang, Pingping and Ren, Jun Tao and Yang, Lifang},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {6},
pages = {5205},
doi = {10.3390/ijms24065205},
url = {https://doi.org/10.3390/ijms24065205}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 2 | |
| 2024 | 10 | |
| 2025 | 14 | |
| 2026 | 13 |
Its field-weighted citation impact is 0.55: it has been cited 0.55 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- nanoparticles
- nanocarriers
- drug delivery
- cardiovascular disease
- atherosclerosis
- myocardial ischemia-reperfusion injury
- aortic aneurysm
- myocarditis
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Yang, P., Ren, J. T., & Yang, L. (2023). Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities. International Journal of Molecular Sciences, 24(6), 5205. https://doi.org/10.3390/ijms24065205
How many times has this paper been cited?
39 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at International Journal of Molecular Sciences: sign in and open the PDF from this page.
Who wrote this paper?
Pingping Yang, Jun Tao Ren, Lifang Yang.
What is the DOI of this paper?
10.3390/ijms24065205, permanently at https://doi.org/10.3390/ijms24065205. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.